Related references
Note: Only part of the references are listed.Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
Jacob Farnebo et al.
BMC CANCER (2014)
The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma
Carmelo Caldarella et al.
RADIOLOGY AND ONCOLOGY (2014)
Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells
Yu Zhu et al.
CANCER SCIENCE (2013)
PET Imaging of Proliferation with Pyrimidines
Omid S. Tehrani et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
PET imaging: implications for the future of therapy monitoring with PET/CT in oncology
Giampaolo Tomasi et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate
Glenn Liu et al.
CLINICAL CANCER RESEARCH (2011)
Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer
Irfan Kayani et al.
CLINICAL CANCER RESEARCH (2011)
Combined Positron Emission Tomography/Computed Tomography in Sunitinib Therapy Assessment of Patients with Metastatic Renal Cell Carcinoma
M. E. Revheim et al.
CLINICAL ONCOLOGY (2011)
Sharpening Wald-type inference in robust regression for small samples
Manuel Koller et al.
COMPUTATIONAL STATISTICS & DATA ANALYSIS (2011)
18F-FDG PET/CT Imaging for an Early Assessment of Response to Sunitinib in Metastatic Renal Carcinoma: Preliminary Study
Laetitia Vercellino et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor
John O. Prior et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NCI-Sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: Safety studies
Alexander M. Spence et al.
MOLECULAR IMAGING AND BIOLOGY (2008)
Fluorine-18 fluorothymidine: A new positron emission radioisotope for renal tumors
Nathan Lawrentschuk et al.
CLINICAL NUCLEAR MEDICINE (2006)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A simplified analysis of [18F]3'-deoxy-3′-fluorothymidine metabolism and retention
AF Shields et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in characterization of solid renal masses
R Kumar et al.
MOLECULAR IMAGING AND BIOLOGY (2005)
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development
G Kelloff et al.
CLINICAL CANCER RESEARCH (2005)
Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma
DE Kang et al.
JOURNAL OF UROLOGY (2004)
Rhebbing up mTOR - New insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis
DJ Kwiatkowski
CANCER BIOLOGY & THERAPY (2003)
Efficiency of [18F]FDG PET in characterising renal cancer and detecting distant metastases:: a comparison with CT
N Aide et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell et al.
BLOOD (2003)
F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma
NS Majhail et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
